Navigation Links
A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
Date:2/14/2014

[TORONTO,Canada, Feb 18, 2014] A protein that has been known until recently as part of a complex communication network within the cell also plays a direct role in regulating sugar metabolism, according to a new study published in the journal Science Signaling (February 18, 2014).

Cell growth and metabolism are tightly controlled processes in our cells. When these functions are disturbed, diseases such as cancer and diabetes occur. Mohamed Soliman, a PhD candidate at the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital, found a unique role for the p66Shc adaptor protein in regulating glucose metabolism and cell growth. This report could lay the foundation for future studies to target adaptor proteins in cancer and diabetes therapy.

Proteins are functional units of cells that assemble in a precise manner to control cellular processes. Specifically, adapter proteins act as linkers or switches to fine tune cellular functions. Soliman and colleagues became interested in studying the p66Shc adaptor protein following observations regarding the role of this protein as a mediator of insulin sensitivity and longevity. Mice deficient in p66Shc have a greatly increased lifespan and show no signs of cancer. These mice also have better glucose tolerance and are resistant to the development of obesity and diabetes. The findings prompted Soliman to take novel approaches to elucidate the mechanism for this. Soliman comments "we found that silencing the adaptor p66Shc in cells, enhances not only glucose metabolism, but also the metabolism of molecules involved in the making the cells building blocks, resulting in overall increased cell growth."

Thus, p66Shc may have evolved to be a switch that responds to nutrient availability. This role for p66Shc as a sensor of energy levels appears to be unique to higher level organisms. Solimans current mentor, Dr. Jim Dennis, explains "the gene responsible for p66Shc protein express
'/>"/>

Contact: Mohamed Soliman
ma.soliman@utoronto.ca
Lunenfeld-Tanenbaum Research Institute
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. SMART heart eases heart ache, targets cardiac patients emotional well-being
4. Target set on cancer gene MCL1
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. IBN discovers human neural stem cells with tumor targeting ability
7. A closer look at PARP-1 reveals potential new drug targets
8. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
9. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
10. Scientists identify new target to battle rheumatoid arthritis
11. Scientists identify possible drug target for acute pancreatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
(Date:11/22/2014)... 2014 Setria® Glutathione is now ... it for use “as a therapeutically active ingredient ... the Therapeutic Goods (Listing) Notice 2014 (No. 5) ... Setria® Glutathione will be exclusivity distributed in Australia ... and imports fine chemicals to Australian manufacturers. TGA ...
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:11/22/2014)... SATURDAY, Nov. 22, 2014 (HealthDay News) -- The wide ... can pose a threat for people with food allergies, ... there are so many types of food allergies that ... over the holidays," Dr. Guha Krishnaswamy, director of allergy ... said in a hospital news release. "If you ...
(Date:11/22/2014)... AZ (PRWEB) November 22, 2014 Hastings ... with decades of experience announces providing clients with the ... The firm offers clients a flexible, intuitive and easy ... combined with having access to Google + allows clients ... order to make a more informed decision when retaining ...
(Date:11/22/2014)... November 22, 2014 Sandbridge Capital, ... investments in the consumer brand sector, acquired a ... will be used to help fund BackJoy’s global ... rollout, particularly its proprietary apparel and footwear lines. ... BackJoy’s Board of Directors. , BackJoy is a ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3
... Development, and Health at Harvard School of Public Health, has ... found that the disease costs a person $3.2 million over ... the new book Understanding Autism: From Basic Neuroscience to Treatment ... Autism,” Ganz says that autism costs $35 billion per year ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... of the Irish Medical Organization (IMO) has expressed his interest ... . Previously, Nora Owen, the party’s former Justice Minister held ... nomination in the Dublin North constituency and is positive about ... held on the 2nd of May. ,‘The people ...
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Researchers from the Simon Bolivar University in Caracas found ... the beans reduced its flatulence capacity// and increased the ... of nutrition especially in the developing countries. ... method of creating flatulence-free beans but not compromising on ...
... University suggests that men are more aware of potential rivals ... The researchers felt that men// become more jealous and wary ... their most fertile. ,The Evolution and Human Behaviour ... with ovulating partners were vary wary of the dominant looking ...
Cached Medicine News:Health News:The Price Of Autism 2Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... Nov. 21, 2014   Rock Creek Pharmaceuticals, Inc., ... Company is scheduled to present at the Biotech Showcase™ ... on January 12-14, 2015. ... of Rock Creek Pharmaceuticals, will present preclinical and clinical ... which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
... 16 , - Promising Efficacy ... Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) ... II studies evaluating,the efficacy, safety and tolerability of QVA149 at ... QVA149 is a novel once-daily,dry powder fixed dose bronchodilator combination ...
... , , ... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from ... 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...
Cached Medicine Technology:QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 2QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 3QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6
... Millbrook Practice Manager® is now known ... (PM). Centricity Physician Office - PM is ... and structure, providing an easily adaptable solution ... physician offices of every specialty and ...
... practice management systems have brought cutting-edge software ... in the world. Today, Intuition PM delivers ... a friendly, intuitive manner. Automate patient registration ... in-office patient processing through wireless hand-held PC's, ...
... Electronic Medical Records module is designed ... costs and increase revenues. It creates ... minimal effort while it streamlines workflow, ... related to patient care outcomes. NextGen ...
... Intuition EMR family of products offers ... range of specialties. Intuition EMR enables ... full electronic record at the point ... spend less time on documentation and ...
Medicine Products: